Intelligence Tailored to Your Industry
Select your sector to see relevant coverage areas
Pharmaceutical
- NDA/ANDA pathway changes
- Drug shortage signals
- cGMP enforcement trends
- Post-market requirements
- → Formulation strategy
- → Supplier qualification
- → Compliance investments
Biotech
- BLA/IND guidance shifts
- Cell & gene therapy policy
- Accelerated pathway updates
- Clinical hold patterns
- → Development timelines
- → Regulatory strategy
- → Board/investor updates
Medical Devices
- 510(k)/PMA trends
- Design control focus areas
- Recall pattern analysis
- International harmonization
- → Submission timing
- → Quality system priorities
- → Market entry planning
Digital Health / SaMD
- Pre-cert program evolution
- AI/ML guidance updates
- Cybersecurity expectations
- Classification decisions
- → Product classification
- → Development approach
- → Regulatory pathway selection
Exactly What You Receive
Based on material regulatory activity
From FDA publication to your inbox
Email + searchable portal archive
Delivery Details
Each brief delivered to your inbox with headline and impact summary
Full archive access, searchable history, organized by topic
Professional tier: Request specific topic analysis (1-2 per month)
Inquiry responses within 24 business hours
Intelligence Coverage Areas
What we monitor and interpret in each intelligence brief
Approval Pathway Changes
NDA, BLA, 510(k), PMA developments that affect submission strategy
Enforcement Actions
Warning letters, consent decrees, recalls that signal compliance focus areas
Policy Shifts
Draft guidances, final rules, policy changes that require operational response
Inspection Patterns
Form 483 trends, import alerts, compliance signals by product type
How Subscribers Use FDA Intelligence
Prepare for Inspection Trends
Understand what FDA inspectors are citing most frequently before your next inspection. Prioritize corrective actions based on current enforcement patterns.
Adjust Validation Strategy
Stay ahead of guidance changes like CSA before competitors implement. Reduce compliance overhead while maintaining inspection readiness.
Pre-Brief Leadership
Inform executives and board members before earnings calls, investor meetings, or product milestones with decision-ready regulatory context.
Reduce Enforcement Exposure
Identify patterns in warning letters and consent decrees that could affect your product portfolio. Proactively address emerging compliance gaps.
Intelligence Brief Format
Clear, specific statement of the regulatory development
5 bullet points covering: what changed, who's affected, timeline, key implications, recommended considerations
Context and analysis explaining the significance and urgency of the development
Assessment by function: Operations, Legal/Compliance, Quality, Commercial/Strategic
Verifiable citations to primary FDA documents and official communications